title: Staging and managing lung tumors using F-18 FDG coincidence detection.
abstract: OBJECTIVE
  Fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomographic (PET) imaging can be a vital tool in the evaluation and preoperative staging of pulmonary neoplasms. Imaging studies on the gamma camera using coincidence PET (co-PET) were introduced recently into clinical practice. This prospective study assessed the efficacy of co-PET for identifying primary tumors, mediastinal lymph node involvement, the presence of distant spread, the effect on disease staging, and influence on disease management.
  
  
  METHODS
  Sixty consecutive patients with 61 lung tumors were enrolled in the study (36 men, 24 women; age range, 32-87 years; mean age, 67 years). Histopathologic confirmation was obtained in 58 patients (59 tumors).
  
  
  RESULTS
  In assessments of a primary lesion to establish its malignant or benign nature, the sensitivity rate of co-PET was 96% (53 of 55 lesions), the specificity rate was 83% (5 of 6 lesions), and the accuracy rate was 95% (58 of 61 lesions). In the co-PET assessment of lymph node involvement in which histopathologic confirmation was obtained (n = 32), the sensitivity rate was 89% (8 of 9 lesions), the specificity rate was 91% (21 of 23 lesions), and the accuracy rate was 91% (29 of 32 lesions). Previously unknown distant metastases were correctly identified in eight patients, but five false-positive lesions were detected in the brain. Disease staging was correctly altered in 20 patients (33%), and disease management plans were changed in 20 patients (33%) based on the co-PET findings. Unnecessary surgery was obviated in six patients (10%). One patient was given the chance for curative treatment based on the findings of the co-PET study.
  
  
  CONCLUSIONS
  The evaluation of patients with lung neoplasms using F-18 FDG coincidence detection appears to be reliable.
authors.affiliation: Department of Nuclear Medicine, The Prince of Wales & Sydney Children's Hospitals, Sydney, New South Wales 2031, Australia.
authors.forename: M R
authors.initials: MR
authors.lastname: Roman
authors.forename: M A
authors.initials: MA
authors.lastname: Rossleigh
authors.forename: S
authors.initials: S
authors.lastname: Angelides
authors.forename: B M
authors.initials: BM
authors.lastname: Walker
authors.forename: J
authors.initials: J
authors.lastname: Dixon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18